Detalhe da pesquisa
1.
Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates.
Mol Cell
; 59(2): 285-97, 2015 Jul 16.
Artigo
Inglês
| MEDLINE | ID: mdl-26118643
2.
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
J Biol Chem
; 295(9): 2601-2613, 2020 02 28.
Artigo
Inglês
| MEDLINE | ID: mdl-31953320
3.
A Combination of Flow and Batch Mode Processes for the Efficient Preparation of mGlu2/3 Receptor Negative Allosteric Modulators (NAMs).
Tetrahedron
; 74(25): 3165-3170, 2018 Jun 21.
Artigo
Inglês
| MEDLINE | ID: mdl-30705468
4.
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteres.
Bioorg Med Chem Lett
; 24(4): 1062-6, 2014 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-24462664
5.
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.
Bioorg Med Chem Lett
; 24(4): 1067-70, 2014 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-24461352
6.
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.
J Neurosci
; 32(25): 8532-44, 2012 Jun 20.
Artigo
Inglês
| MEDLINE | ID: mdl-22723693
7.
Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: the continued optimization of an MLPCN probe molecule.
Bioorg Med Chem Lett
; 23(6): 1860-4, 2013 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23416001
8.
Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule.
Bioorg Med Chem Lett
; 23(2): 412-6, 2013 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23237839
9.
Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia.
Bioorg Med Chem Lett
; 23(1): 346-50, 2013 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23177787
10.
Further exploration of M1 allosteric agonists: subtle structural changes abolish M1 allosteric agonism and result in pan-mAChR orthosteric antagonism.
Bioorg Med Chem Lett
; 23(1): 223-7, 2013 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23200253
11.
Synthesis and biological characterization of a series of novel diaryl amide M1 antagonists.
Bioorg Med Chem Lett
; 22(22): 6923-8, 2012 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23062550
12.
Corrigendum to "Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres" [Bioorg. Med. Chem. Lett. 24 (2014) 1062-1066].
Bioorg Med Chem Lett
; 27(9): 2079, 2017 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28347668
13.
Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.
Bioorg Med Chem Lett
; 22(2): 1044-8, 2012 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-22197142
14.
Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor.
Bioorg Med Chem Lett
; 22(15): 5084-8, 2012 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22738637
15.
Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.
Bioorg Med Chem Lett
; 22(12): 3921-5, 2012 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-22607673
16.
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.
Bioorg Med Chem Lett
; 22(15): 5035-40, 2012 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22749871
17.
Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor.
Bioorg Med Chem Lett
; 22(10): 3467-72, 2012 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-22507963
18.
Development and use of a high-throughput screen to identify novel modulators of the corticotropin releasing factor binding protein.
SLAS Discov
; 27(8): 448-459, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36210051
19.
Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia.
J Med Chem
; 65(2): 1352-1369, 2022 01 27.
Artigo
Inglês
| MEDLINE | ID: mdl-34807584
20.
Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
Cancer Lett
; 534: 215613, 2022 05 28.
Artigo
Inglês
| MEDLINE | ID: mdl-35276290